Ocrelizumab: long-term data
Biotin in progressive MS
Increased myocardial infarction risk in MS
No adverse impact with frequent gadolinium exposure
Emerging treatment approaches: targeting Bruton’s tyrosine kinase

Ocrelizumab: long-term data
The open-label extension of the OPERA I/II trials of ocrelizumab reports sustained efficacy for up to 5 years (Hauser et al. ECTRIMS 2018; abstract P590). Following the 96-week double-blind phase, subjects continued on ocrelizumab or were switched from interferon-beta to ocrelizumab. The overall continuation rate for the 3-year extension period was 88.6%. In the subgroup on continuous ocrelizumab, the annualized relapse rate (ARR) declined from 0.11 in year 2 to 0.07 in year 5; the proportion with 6-month confirmed disability progression increased from 7.7% in year 2, to 13.9% in year 4 and 16.1% in year 5. In the group switched from IFN-beta, there was a significant reduction in ARR, from 0.20 prior to switching to 0.10 in the year after switching. ARR reductions were not significant thereafter (ARR 0.07 in year 5). The proportion with 6-month confirmed disability progression was 12.0% in the year prior to switching, increasing to 15.6% in year 1 of ocrelizumab, 18.1% in year 2, and 21.3% in year 3.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page